Mucolysin Antibiotico

What do you feel about the cost of the medicine? Is it expensive?

Mucolysin Antibiotico uses

Mucolysin Antibiotico consists of Erythromycin, Tiopronin Sodium.


Pharmacological action

Mucolysin Antibiotico is a macrolide antibiotic. Has bacteriostatic action. However at higher doses against susceptible organisms has a bactericidal effect. Mucolysin Antibiotico (Erythromycin) is reversibly bound to the ribosome of bacteria, thereby inhibiting protein synthesis. Mucolysin Antibiotico (Erythromycin) is active against gram-positive bacteria: Staphylococcus spp. (strains producing and not producing penicillinase), Streptococcus spp. (including Streptococcus pneumoniae); gram-negative bacteria: Neisseria gonorrhoeae, Haemophilus influenzae, Bordetella pertussis, Brucella spp., Legionella spp., Bacillus anthracis, Corynebacterium diphtheriae; anaerobic bacteria: Clostridium spp. Mucolysin Antibiotico (Erythromycin) is also active against Mycoplasma spp., Chlamydia spp., Spirochaetaceae, Rickettsia spp. To Mucolysin Antibiotico (Erythromycin) resistant gram-negative bacilli, including Escherichia coli, Pseudomonas aeruginosa, Shigella spp., Salmonella spp.


Mucolysin Antibiotico (Erythromycin) bioavailability is 30-65%. Distributed in most tissues and body fluids. Plasma protein binding is 70-90%. Metabolised in the liver, partly with the formation of inactive metabolites. T1/2 is 1.4-2 hours. It is derived from bile and urine.

Why is Mucolysin Antibiotico prescribed?

Infectious-inflammatory diseases caused by microorganisms sensitive to Mucolysin Antibiotico (Erythromycin), including diphtheria, pertussis, trachoma, brucellosis, a disease Legionnaires, sore throat, scarlet fever, otitis media, sinusitis, cholecystitis, pneumonia, gonorrhea, syphilis. Also Mucolysin Antibiotico (Erythromycin) used for the treatment of infectious-inflammatory diseases caused by pathogens (eg staphylococci) are resistant to penicillin, tetracycline, chloramphenicol, streptomycin.

For external use: acne vulgaris.

For local use: the infectious-inflammatory diseases of eyes.


Dosage and administration

Mucolysin Antibiotico prescribed individually depending on the location and severity of infection, the sensitivity of the parasite. In adults use a daily dose of 1-4 g. Children under the age of 3 months - 20-40 mg / kg / day, aged from 4 months to 18 years - 30-50 mg / kg / day. Multiplicity is 4 times / day. The treatment course - 5-14 days after the disappearance of symptoms treatment should be continued for a further 2 days. Accepts up to 1 hour before eating or 2-3 hours after eating.

Solution for external applications lubricate the affected skin.

The ointment is applied to the affected area and in diseases of the eye lay behind the lower eyelid. The dose, frequency and duration of application is determined individually.

Mucolysin Antibiotico (Erythromycin) side effects, adverse reactions

Digestive system: nausea, vomiting, epigastric pain, cholestatic jaundice, tenesmus, diarrhea, dysbacteriosis; rarely - pseudomembranous enterocolitis, abnormal liver function, increase in liver transaminases, pancreatitis.

Allergic reactions: skin rash, urticaria, eosinophilia, rarely - anaphylactic shock.

Effects due to the influence of chemotherapy: oral candidiasis, vaginal candidiasis.

From the senses: the reversible ototoxicity - hearing loss and / or tinnitus (in the application of high doses - more than 4 g / day).

Since the cardiovascular system: rarely - tachycardia, prolongation of the QT interval on ECG, flickering and / or atrial flutter (patients with long QT interval on the ECG).

Local reactions: phlebitis at the site of / in the introduction.

Mucolysin Antibiotico contraindications

Jaundice in history, marked disturbances of liver function, hypersensitivity to macrolides.

Using during pregnancy and breastfeeding

Mucolysin Antibiotico crosses the placental barrier, excreted in breast milk.

In the application of Mucolysin Antibiotico (Erythromycin) in pregnancy should assess the intended benefits to the mother and the potential risk to the fetus. If necessary, use during lactation should decide on the termination of breastfeeding.


Special instructions

With careful use Mucolysin Antibiotico (Erythromycin) when disorders of liver function and / or kidneys. Medications that increase the acidity of gastric juice and acidic drinks inactivate Mucolysin Antibiotico (Erythromycin). Mucolysin Antibiotico (Erythromycin) can not drink milk and dairy products.

Precautionary measures

The use of Mucolysin Antibiotico containing benzene for IV injection sometimes accompanied by the development of a fatal syndrome Gaspinga in children, as well as acute hepatitis drug in adults and children.

Mucolysin Antibiotico (Erythromycin) drug interactions

With simultaneous use of Mucolysin Antibiotico (Erythromycin) with theophylline, aminophylline, caffeine, there is an increase in their concentration in blood plasma and thus increases the risk of toxic effects.

Mucolysin Antibiotico (Erythromycin) increases the concentrations of cyclosporine in the blood plasma and may increase the risk of nephrotoxicity.

Drugs that block tubular secretion prolongs T1/2 of Mucolysin Antibiotico (Erythromycin).

Incompatible with lincomycin, clindamycin and chloramphenicol (antagonism).

Mucolysin Antibiotico (Erythromycin) reduces the bactericidal action of beta-lactam antibiotics (penicillins, cephalosporins, carbapenems).

With simultaneous use of Mucolysin Antibiotico (Erythromycin) increases the concentration of theophylline.

At the same time receiving chemotherapy, which is carried metabolism in the liver (carbamazepine, valproic acid, hexobarbital, phenytoin, alfentanil, dizopiramid, lovastatin, bromocriptine), may increase the concentration of these drugs in plasma (an inhibitor of microsomal liver enzymes).

IV injection of Mucolysin Antibiotico (Erythromycin) increases the effects of ethanol (accelerating gastric emptying and decrease the duration of alcohol dehydrogenase in the gastric mucosa).

Mucolysin Antibiotico (Erythromycin) reduces the clearance of triazolam and midazolam and therefore may increase the pharmacological effects of benzodiazepines.

At the same time taking with terfenadine or astemizole may develop arrhythmias (fibrillation and ventricular flutter, ventricular tachycardia, until death); with dihydroergotamine or non hydrated ergot alkaloids may vasoconstriction to spasm, dysesthesia.

With simultaneous application Mucolysin Antibiotico (Erythromycin) slows elimination (increases the effect) of methylprednisolone, felodipine and anticoagulants of cumarine series.

In a joint appointment with lovastatin increased rhabdomyolysis.

Mucolysin Antibiotico (Erythromycin) increases the bioavailability of digoxin.

Mucolysin Antibiotico (Erythromycin) reduces the effectiveness of hormonal contraceptives.

Mucolysin Antibiotico in case of emergency / overdose

Symptoms: disruption of the liver until the acute liver failure, and hearing loss.

Treatment: gastric lavage, forced diuresis, hemo-and peritoneal dialysis. Produced a constant monitoring of vital functions (ECG, electrolyte composition of blood).

Tiopronin Sodium:


Mucolysin Antibiotico (Tiopronin Sodium)® (Tiopronin) is a reducing and complexing thiol compound. Mucolysin Antibiotico (Tiopronin Sodium) is N-(2-Mercaptopropionyl) glycine and has the following structure:

Mucolysin Antibiotico (Tiopronin Sodium) has the empirical formula C5H9NO3S and a molecular weight of 163.20. In this drug product Mucolysin Antibiotico (Tiopronin Sodium) exists as a dl racemic mixture.

Mucolysin Antibiotico (Tiopronin Sodium) is a white crystalline powder which is freely soluble in water.

Mucolysin Antibiotico (Tiopronin Sodium)® tablets are white, sugar coated tablets, each containing 100 mg. of Mucolysin Antibiotico (Tiopronin Sodium) and are taken orally.

Inactive ingredients: Calcium carbonate, carnauba wax, ethyl cellulose, Eudragit E 100, hydroxy-propyl cellulose, lactose, magnesium stearate, povidone, sugar, talc, titanium dioxide.



Mucolysin Antibiotico (Tiopronin Sodium)® is an active reducing agent which undergoes thiol-disulfide exchange with cystine to form a mixed disulfide of Thiola-cysteine.

From this reaction, a water-soluble mixed disulfide is formed and the amount of sparingly soluble cystine is reduced. When Mucolysin Antibiotico (Tiopronin Sodium)® is given orally, up to 48% of dose appears in urine during the first 4 hours and up to 78% by 72 hours. Thus, in patients with cystinuria, sufficient amount of Mucolysin Antibiotico (Tiopronin Sodium)® or its active metabolites could appear in urine to react with cystine, lowering cystine excretion.

The decrement in urinary cystine produced by Mucolysin Antibiotico (Tiopronin Sodium)® is generally proportional to the dose. A reduction in urinary cystine of 250-350 mg/day at a Mucolysin Antibiotico (Tiopronin Sodium)® dosage of 1 g/day, and a decline of approximately 500 mg/day at a dosage of 2 g/day, might be expected. Mucolysin Antibiotico (Tiopronin Sodium)® causes a sustained reduction in cystine excretion without apparent loss of effectiveness. Mucolysin Antibiotico (Tiopronin Sodium)® has a rapid onset and offset of action, showing a fall in cystine excretion on the first day of administration and a rise on the first day of drug withdrawal.




Mucolysin Antibiotico (Tiopronin Sodium)® is indicated for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria with urinary cystine greater than 500 mg/day, who are resistant to treatment with conservative measures of high fluid intake, alkali and diet modification, or who have adverse reactions to d-penicillamine.

Cystine stones typically occur in approximately 10,000 persons in the United States who are homozygous for cystinuria. These persons excrete abnormal amounts of cystine in urine of over 250 mg/g creatinine, as well as excessive amounts of other dibasic amino acids (lysine, arginine and ornithine). In addition, they show varying intestinal transport defects for these same amino acids. The stone formation is the result of poor aqueous solubility of cystine.

Since there are no known inhibitors of the crystallization of cystine, the stone formation is determined primarily by the urinary supersaturation of cystine. Thus, cystine stones could theoretically form whenever urinary cystine concentration exceeds the solubility limit. Cystine solubility in urine is pH-dependent, and ranges from 170-300 mg/liter at pH 5, 190-400 mg/liter at pH 7 and 220-500 mg/liter at pH 7.5.

The goal of therapy is to reduce urinary cystine concentration below its solubility limit. It may be accomplished by dietary means aimed at reducing cystine synthesis and by a high fluid intake in order to increase urine volume and thereby lower cystine concentration.

Unfortunately, the above conservative measures alone may be ineffective in controlling cystine stone formation in some homozygous patients with severe cystinuria (urinary cystine exceeding 500 mg/day). In such patients, d-penicillamine has been used as an additional therapy. Like Mucolysin Antibiotico (Tiopronin Sodium) , dpenicillamine undergoes thiol-disulfide exchange with cystine, thereby lowering the amount of sparingly soluble cystine in urine.

However, d-penicillamine treatment is frequently accompanied by adverse reactions, such as dermatologic complications, hypersensitivity reactions, hematologic abnormalities and renal disturbances. Mucolysin Antibiotico (Tiopronin Sodium)® may have a particular therapeutic role in such patients.



The use of Mucolysin Antibiotico (Tiopronin Sodium)® during pregnancy is contraindicated, except in those with severe cystinuria where the anticipated benefit of inhibited stone formation clearly outweighs possible hazards of treatment.

Mucolysin Antibiotico (Tiopronin Sodium)® should not be begun again in patients with a prior history of developing agranulocytosis, aplastic anemia or thrombocytopenia on this medication.

Mothers maintained on Mucolysin Antibiotico (Tiopronin Sodium)® treatment should not nurse their infants.


Despite apparent lower toxicity of Mucolysin Antibiotico (Tiopronin Sodium) , Mucolysin Antibiotico (Tiopronin Sodium)® may potentially cause all the serious adverse reactions reported for d-penicillamine. Thus, although no death has been reported to result directly from Mucolysin Antibiotico (Tiopronin Sodium)® treatment, a fatal outcome from Mucolysin Antibiotico (Tiopronin Sodium)® is possible, as has been reported with d-penicillamine therapy from such complications as aplastic anemia, agranulocytosis, thrombocytopenia, Goodpasture’s syndrome or myasthenia gravis.

Leukopenia of the granulocytic series may develop without eosinophilia. Thrombocytopenia may be immunologic in origin or occur on an idiosyncratic basis. The reduction in peripheral blood white count to less than 3500/cubic mm or in platelet count to below 100,000 cubic mm mandates cessation of therapy. Patients should be instructed to report promptly the occurrence of any symptom or sign of these hematological abnormalities, such as fever, sore throat, chills, bleeding or easy bruisability.

Proteinuria, sometimes sufficiently severe to cause nephrotic syndrome, may develop from membranous glomerulopathy. A close observation of affected patients is mandatory.

The following complications, though rare, have been reported during d-penicillamine therapy and could occur during Mucolysin Antibiotico (Tiopronin Sodium)® treatment. When there are abnormal urinary findings associated with hemoptysis and pulmonary infiltrates suggestive of Goodpasture’s syndrome, Mucolysin Antibiotico (Tiopronin Sodium)® treatment should be stopped. Appearance of myasthenic syndrome or myasthenia gravis requires cessation of treatment. When pemphigus-type reactions develop, Mucolysin Antibiotico (Tiopronin Sodium)® therapy should be stopped. Steroid treatment may be necessary.


Patients should be advised of the potential development of complications and to report promptly the occurrence of any symptom or sign of them.

To help monitor potential complications, the following tests are recommended: peripheral blood counts, direct platelet count, hemoglobin, serum albumin, liver function tests, 24-hour urinary protein and routine urinalysis at 3- 6 month intervals during treatment. In order to assess effect on stone disease, urinary cystine analysis should be monitored frequently during the first 6 months when the optimum dose schedule is being determined, and at 6-month intervals thereafter. Abdominal roentogenogram (KUB) is advised on a yearly basis to monitor the size and appearance/disappearance of stone(s).

  • CARCINOGENESIS, MUTAGENESIS, IMPAIRMENT OF FERTILITY: Long-term carcino-genicity studies in animals have not been performed. High doses of Mucolysin Antibiotico (Tiopronin Sodium)® in experimental animals have been shown to interfere with maintenance of pregnancy and viability of the fetus.

  • USE IN PREGNANCY: Pregnancy category C. D-penicillamine has been shown to cause skeletal defects and cleft palates in the fetus when given to pregnant rats at 10 times the dose recommended for human use. A similar teratogenicity might be expected for Mucolysin Antibiotico (Tiopronin Sodium)® although no such findings could be related to the drug in studies in mice and rats at doses up to 10 times the highest recommended human dose.

    There are no adequate and well-controlled studies in pregnant women. Mucolysin Antibiotico (Tiopronin Sodium)® should be used during pregnancy only if the potential benefit justifies potential risk to the fetus.

  • NURSING MOTHERS: Because Mucolysin Antibiotico (Tiopronin Sodium)® may be excreted in milk and because of the potential serious adverse reactions of nursing infants from Mucolysin Antibiotico (Tiopronin Sodium)®, mothers taking Mucolysin Antibiotico (Tiopronin Sodium)® should not nurse their infants.

  • PEDIATRIC USE: Safety and effectiveness below the age of 9 have not been established.


Some patients may develop drug fever, usually during the first month of therapy. Mucolysin Antibiotico (Tiopronin Sodium)® treatment should be discontinued until the fever subsides. It may be reinstated at a small dose, with a gradual increase in dosage until the desired level is achieved.

A generalized rash (erythematous, maculopapular or morbilliform) accompanied by pruritis may develop during the first few months of treatment. It may be controlled by antihistamine therapy, typically recedes when Mucolysin Antibiotico (Tiopronin Sodium)® treatment is discontinued, and seldom recurs when Mucolysin Antibiotico (Tiopronin Sodium)® treatment is restarted at a lower dosage. Less commonly, rash may appear late in the course of treatment (of more than 6 months). Located usually in the trunk, the late rash is associated with intense pruritis, recedes slowly after discontinuing treatment, and usually recurs upon resumption of treatment.

A drug reaction simulating lupus erythematous, manifested by fever, arthralgia and lymphadenopathy may develop. It may be associated with a positive antinuclear antibody test, but not necessarily with nephropathy. It may require discontinuance of Mucolysin Antibiotico (Tiopronin Sodium)® treatment.

A reduction in taste perception may develop. It is believed to be the result of chelation of trace metals by Mucolysin Antibiotico (Tiopronin Sodium) . Hypogeusia is often self-limiting.

Unlike during d-penicillamine therapy, vitamin B6 deficiency is uncommonly associated with Mucolysin Antibiotico (Tiopronin Sodium)® treatment.

Some patients may complain of wrinkling and friability of skin. This complication usually occurs after long-term treatment, and is believed to result from the effect of Mucolysin Antibiotico (Tiopronin Sodium)® on collagen.

A multiclinic trial involving 66 cystinuric patients in the United States indicated that Mucolysin Antibiotico (Tiopronin Sodium)® is associated with fewer or less severe adverse reactions than d-penicillamine. Among those who had to stop taking d-penicillamine due to toxicity, 64.7% could take Mucolysin Antibiotico (Tiopronin Sodium)®. In those without prior history of d-penicillamine treatment, only 5.9% developed reactions of sufficient severity to require Mucolysin Antibiotico (Tiopronin Sodium)® withdrawal. A review of available literature supports the findings from this trial.

Despite this apparent reduced toxicity to Mucolysin Antibiotico (Tiopronin Sodium)® relative to d-penicillamine, Mucolysin Antibiotico (Tiopronin Sodium)® treatment may potentially be associated with all the adverse reactions reported with d-penicillamine. They include:

           Gastrointestinal side-effects (nausea, emesis, diarrhea or softstools, anorexia, abdominal pain, bloating or flatus) in about 1 in 6 patients;

           Impairment in taste and smell in about 1 in 25 patients;

           Dermatologic complications (pharyngitis, oral ulcers, rash, ecchymosis, prurites, uritcaria, warts, skin wrinkling, pemphigus, elastosis perforans serpiginosa) in about 1 in 6 patients;

           Hypersensitivity reactions (laryngeal edema, dyspnea, respiratory distress, fever, chills, arthralgia, weakness, fatigue, myalgia, adenopathy) in about 1 in 25 patients;

           Hematologic abnormalities (increased bleeding, anemia, leukopenia, thrombocytopenia, eosinophilia) in about 1 in 25 patients;

           Renal complications (proteinuria, nephrotic syndrome, hematuria) in about 1 in 20 patients;

           Pulmonary manifestations (bronchiolitis, hemoptysis, pulmonary infiltrates, dyspnea) in about 1 in 50 patients;

           Neurologic complications (myasthenic syndrome) in about 1 in 50 patients.

These reactions are more likely to develop during Mucolysin Antibiotico (Tiopronin Sodium)® therapy among patients who had previously shown toxicity to d-penicillamine.

In patients who had previously manifested adverse reactions to d-penicillamine, adverse reactions to Mucolysin Antibiotico (Tiopronin Sodium)® are more likely to occur than in patients who took Mucolysin Antibiotico (Tiopronin Sodium)® for the first time. A close supervision with a careful monitoring of potential side effects is mandatory during Mucolysin Antibiotico (Tiopronin Sodium)® treatment. Patients should be told to report promptly any symptoms suggesting toxicity. The treatment with Mucolysin Antibiotico (Tiopronin Sodium)® should be stopped if severe toxicity develops.

Jaundice and abnormal liver function tests have been reported during Mucolysin Antibiotico (Tiopronin Sodium)® therapy for non-cystinuric conditions. A direct cause and effect relationship, based upon these foreign reports, has not been established. Although such complications were not encountered in the small multi-center trials in the United States, patients should be carefully monitored and if any abnormalities are noted, the drug should be discontinued and the patient treated by appropriate measures.


It is recommended that a conservative treatment program should be attempted first. At least 3 liters of fluid (10-10 oz. glassfuls) should be provided, including two glasses with each meal and at bedtime. The patients should be expected to awake at night to urinate; they should drink two more glasses of fluids before returning to bed. Additional fluids should be consumed if there is excessive sweating or intestinal fluid loss. A minimum urine output of 2 liters/day on a consistent basis should be sought. A modest amount of alkali should be provided in order to maintain urinary pH at a high normal range (6.5-7.0). Potassium alkali are advantageous over sodium alkali, because they do not cause hypercalciuria and are less likely to cause the complication of calcium stones.

Excessive alkali therapy is not advisable. When urinary pH increases above 7.0 with alkali therapy, the complication of calcium phosphate nephrolithiasis may ensue because of the enhanced urinary supersaturation of hydroxyapatite in an alkaline environment.

In patients who continue to form cystine stones on the above conservative program, Mucolysin Antibiotico (Tiopronin Sodium)® may be added to the treatment program. Mucolysin Antibiotico (Tiopronin Sodium)® may also be substituted for d-penicillamine in patients who have developed toxicity to the latter drug. In both situations, the conservative treatment program should be continued.

The dose of Mucolysin Antibiotico (Tiopronin Sodium)® should not be arbitrary but should be based on that amount required to reduce urinary cystine concentration to below its solubility limit (generally <250 mg/liter). The extent of the decline in cystine excretion is generally dependent on the Mucolysin Antibiotico (Tiopronin Sodium)® dosage.

Mucolysin Antibiotico (Tiopronin Sodium)® may be begun at a dosage of 800 mg/day in adult patients with cystine stones. In a multiclinic trial, average dose of Mucolysin Antibiotico (Tiopronin Sodium)® was about 1000 mg/day. However, some patients require a smaller dose. In children, initial dosage may be based on 15 mg/kg/day. Urinary cystine should be measured at 1 month after Mucolysin Antibiotico (Tiopronin Sodium)® treatment, and every 3 months thereafter. Mucolysin Antibiotico (Tiopronin Sodium)® dosage should be readjusted depending on the urinary cystine value. Whenever possible, Mucolysin Antibiotico (Tiopronin Sodium)® should be given in divided doses 3 times/day at least one hour before or 2 hours after meals.

In patients who had shown severe toxicity to d-penicillamine, Mucolysin Antibiotico (Tiopronin Sodium)® might be begun at a lower dosage.


Mucolysin Antibiotico (Tiopronin Sodium)® (NDC 0178-0900-01), is available for oral administration as 100 mg. round, white, sugar coated tablets in bottles of 100 tablets each. Each tablet is imprinted in red with “M” on one side and blank on the other side. Store at 25°C (77°F); excursions permitted to 15- 30°C (59-86°F).

C05 Rev 010060


Mucolysin Antibiotico (Tiopronin Sodium)® Label

NDC: 0178-0900-01

Mucolysin Antibiotico pharmaceutical active ingredients containing related brand and generic drugs:

Active ingredient is the part of the drug or medicine which is biologically active. This portion of the drug is responsible for the main action of the drug which is intended to cure or reduce the symptom or disease. The other portions of the drug which are inactive are called excipients; there role is to act as vehicle or binder. In contrast to active ingredient, the inactive ingredient's role is not significant in the cure or treatment of the disease. There can be one or more active ingredients in a drug.

Mucolysin Antibiotico available forms, composition, doses:

Form of the medicine is the form in which the medicine is marketed in the market, for example, a medicine X can be in the form of capsule or the form of chewable tablet or the form of tablet. Sometimes same medicine can be available as injection form. Each medicine cannot be in all forms but can be marketed in 1, 2, or 3 forms which the pharmaceutical company decided based on various background research results.
Composition is the list of ingredients which combinedly form a medicine. Both active ingredients and inactive ingredients form the composition. The active ingredient gives the desired therapeutic effect whereas the inactive ingredient helps in making the medicine stable.
Doses are various strengths of the medicine like 10mg, 20mg, 30mg and so on. Each medicine comes in various doses which is decided by the manufacturer, that is, pharmaceutical company. The dose is decided on the severity of the symptom or disease.

Mucolysin Antibiotico destination | category:

Destination is defined as the organism to which the drug or medicine is targeted. For most of the drugs what we discuss, human is the drug destination.
Drug category can be defined as major classification of the drug. For example, an antihistaminic or an antipyretic or anti anginal or pain killer, anti-inflammatory or so.

Mucolysin Antibiotico Anatomical Therapeutic Chemical codes:

A medicine is classified depending on the organ or system it acts [Anatomical], based on what result it gives on what disease, symptom [Therapeutical], based on chemical composition [Chemical]. It is called as ATC code. The code is based on Active ingredients of the medicine. A medicine can have different codes as sometimes it acts on different organs for different indications. Same way, different brands with same active ingredients and same indications can have same ATC code.

Mucolysin Antibiotico pharmaceutical companies:

Pharmaceutical companies are drug manufacturing companies that help in complete development of the drug from the background research to formation, clinical trials, release of the drug into the market and marketing of the drug.
Researchers are the persons who are responsible for the scientific research and is responsible for all the background clinical trials that resulted in the development of the drug.



  2. Dailymed."TIOPRONIN: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". (accessed August 28, 2018).
  3. Dailymed."ERYTHROMYCIN: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". (accessed August 28, 2018).

Frequently asked Questions

Can i drive or operate heavy machine after consuming Mucolysin Antibiotico?

Depending on the reaction of the Mucolysin Antibiotico after taken, if you are feeling dizziness, drowsiness or any weakness as a reaction on your body, Then consider Mucolysin Antibiotico not safe to drive or operate heavy machine after consumption. Meaning that, do not drive or operate heavy duty machines after taking the capsule if the capsule has a strange reaction on your body like dizziness, drowsiness. As prescribed by a pharmacist, it is dangerous to take alcohol while taking medicines as it exposed patients to drowsiness and health risk. Please take note of such effect most especially when taking Primosa capsule. It's advisable to consult your doctor on time for a proper recommendation and medical consultations.

Is Mucolysin Antibiotico addictive or habit forming?

Medicines are not designed with the mind of creating an addiction or abuse on the health of the users. Addictive Medicine is categorically called Controlled substances by the government. For instance, Schedule H or X in India and schedule II-V in the US are controlled substances.

Please consult the medicine instruction manual on how to use and ensure it is not a controlled substance.In conclusion, self medication is a killer to your health. Consult your doctor for a proper prescription, recommendation, and guidiance.


Review conducted a study on Mucolysin Antibiotico, and the result of the survey is set out below. It is noteworthy that the product of the survey is based on the perception and impressions of the visitors of the website as well as the views of Mucolysin Antibiotico consumers. We, as a result of this, advice that you do not base your therapeutic or medical decisions on this result, but rather consult your certified medical experts for their recommendations.

Visitor reports

Visitor reported useful

No survey data has been collected yet

Visitor reported side effects

No survey data has been collected yet

Visitor reported price estimates

No survey data has been collected yet

Visitor reported frequency of use

No survey data has been collected yet

Visitor reported doses

No survey data has been collected yet

Visitor reported time for results

No survey data has been collected yet

Visitor reported administration

No survey data has been collected yet

Visitor reported age

No survey data has been collected yet

Visitor reviews

There are no reviews yet. Be the first to write one!

Your name: 
Spam protection:  < Type 13 here

The information was verified by Dr. Arunabha Ray, MD Pharmacology

© 2002 - 2021 "". All Rights Reserved